Targeting Plk1 to enhance efficacy of Olaparib in castration-resistant prostate cancer

Olaparib is a FDA-approved PARP inhibitor (PARPi) that has shown promise as a synthetic lethal treatment approach for BRCA-mutant castration-resistant prostate cancer (CRPC) in clinical use. However, emerging data has also shown that even BRCA-mutant cells may be resistant to PARPi. The mechanistic...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Mol Cancer Ther
Asıl Yazarlar: Li, Jie, Wang, Ruixin, Kong, Yifan, Broman, Meaghan M., Carlock, Colin, Chen, Long, Li, Zhiguo, Farah, Elia, Ratliff, Timothy L., Liu, Xiaoqi
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2017
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5337144/
https://ncbi.nlm.nih.gov/pubmed/28069876
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-16-0361
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller